Therapeutic antibodies have proven to be effective and safe treatments for various diseases, and understanding the binding of therapeutic antibodies to Fc receptors provides insights into their mechanism of action (MOA), efficacy, and safety. During early drug development, as potential therapeutic antibodies are selected and engineered, changes in Fc receptor affinity can be indicative of changes in effector function and serum half-life.
In this application note, we demonstrate how AlphaLISA® biochemical Fc receptor binding assays provide easy, robust methods to measure the binding of potential therapeutic antibodies to human Fc receptor proteins.